Trial intelligence / Profile preview

KAI-1678 in SCI-associated Neuropathic Pain

NCT01135108Phase 2Completed

Sponsor
KAI Pharmaceuticals
Start
Mar 2009
Primary completion
Mar 2010
Modality
Peptides, Small Molecules
Countries
1
01

Overview

A Phase 2 trial of KAI-1678 in central neuropathic pain (CNP), sponsored by KAI Pharmaceuticals. Started Mar 2009; status: completed.

02

Drugs

KAI-1678
03

Conditions

central neuropathic pain (CNP)

Beyond the preview

Go deeper on NCT01135108.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01135108.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call